166 related articles for article (PubMed ID: 33299560)
1. Down-regulation of
Soerohardjo I; Widodo I; Heriyanto DS; Zulfiqqar A; Anwar SL
Ann Med Surg (Lond); 2020 Dec; 60():549-554. PubMed ID: 33299560
[TBL] [Abstract][Full Text] [Related]
2. Development and Independent Validation of a Prognostic Gene Expression Signature Based on RB1, PTEN, and TP53 in Metastatic Hormone-sensitive Prostate Cancer Patients.
Jiménez N; Garcia de Herreros M; Reig Ò; Marín-Aguilera M; Aversa C; Ferrer-Mileo L; García-Esteve S; Rodríguez-Carunchio L; Trias I; Font A; Rodriguez-Vida A; Climent MÁ; Cros S; Chirivella I; Domènech M; Figols M; Carles J; Suárez C; Herrero Rivera D; González-Billalabeitia E; Cívico C; Sala-González N; Ruiz de Porras V; Ribal MJ; Prat A; Mellado B
Eur Urol Oncol; 2024 Mar; ():. PubMed ID: 38429210
[TBL] [Abstract][Full Text] [Related]
3. Role of somatostatin receptor SSRT5-AS1 in predicting biomarkers of primary androgen deprivation therapy on prostate cancer in Indonesian population.
Soerohardjo I; Widodo I; Zulfiqqar A; Heriyanto DS; Anwar SL
Med J Malaysia; 2022 Jul; 77(Suppl 1):1-4. PubMed ID: 35899879
[TBL] [Abstract][Full Text] [Related]
4. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N;
Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502
[TBL] [Abstract][Full Text] [Related]
5. The Combined Effect of Downregulated RB1 and Overexpressed lncRNA SSTRS-AS1 on Prediction Time to Castration-Resistant Prostate Cancer: Indonesian Cohort Studies.
Soerohardjo I; Zulfiqqar A; Widodo I; Setyo Heriyanto D; Lukman Anwar S
Turk J Urol; 2022 Mar; 48(2):112-117. PubMed ID: 35420053
[TBL] [Abstract][Full Text] [Related]
6. The predictive value of ERG protein expression for development of castration-resistant prostate cancer in hormone-naïve advanced prostate cancer treated with primary androgen deprivation therapy.
Berg KD; Røder MA; Thomsen FB; Vainer B; Gerds TA; Brasso K; Iversen P
Prostate; 2015 Oct; 75(14):1499-509. PubMed ID: 26053696
[TBL] [Abstract][Full Text] [Related]
7. Factors predicting progression to castrate-resistant prostate cancer in patients with advanced prostate cancer receiving long-term androgen-deprivation therapy.
de la Taille A; Martínez-Piñeiro L; Cabri P; Houchard A; Schalken J;
BJU Int; 2017 Jan; 119(1):74-81. PubMed ID: 26919403
[TBL] [Abstract][Full Text] [Related]
8. [Predictive factor analysis of time to progression of castration-resistant prostate cancer after androgen deprivation therapy].
Ji GJ; Huang C; Song G; Li XS; Song Y; Zhou LQ
Beijing Da Xue Xue Bao Yi Xue Ban; 2017 Aug; 49(4):657-662. PubMed ID: 28816284
[TBL] [Abstract][Full Text] [Related]
9. Transcriptional Profile Associated with Clinical Outcomes in Metastatic Hormone-Sensitive Prostate Cancer Treated with Androgen Deprivation and Docetaxel.
Jiménez N; Reig Ò; Marín-Aguilera M; Aversa C; Ferrer-Mileo L; Font A; Rodriguez-Vida A; Climent MÁ; Cros S; Chirivella I; Domenech M; Figols M; González-Billalabeitia E; Jiménez Peralta D; Rodríguez-Carunchio L; García-Esteve S; Garcia de Herreros M; Ribal MJ; Prat A; Mellado B
Cancers (Basel); 2022 Sep; 14(19):. PubMed ID: 36230681
[TBL] [Abstract][Full Text] [Related]
10. Transcript Levels of Androgen Receptor Variant 7 and Ubiquitin-Conjugating Enzyme 2C in Hormone Sensitive Prostate Cancer and Castration-Resistant Prostate Cancer.
Lee CH; Ku JY; Ha JM; Bae SS; Lee JZ; Kim CS; Ha HK
Prostate; 2017 Jan; 77(1):60-71. PubMed ID: 27550197
[TBL] [Abstract][Full Text] [Related]
11. Activation of ONECUT2 by RB1 loss in castration-resistant prostate cancer.
Qian C; Yang Q; Freedland SJ; Di Vizio D; Ellis L; You S; Freeman MR
Am J Clin Exp Urol; 2022; 10(6):397-407. PubMed ID: 36636695
[TBL] [Abstract][Full Text] [Related]
12. Compound Genomic Alterations of TP53, PTEN, and RB1 Tumor Suppressors in Localized and Metastatic Prostate Cancer.
Hamid AA; Gray KP; Shaw G; MacConaill LE; Evan C; Bernard B; Loda M; Corcoran NM; Van Allen EM; Choudhury AD; Sweeney CJ
Eur Urol; 2019 Jul; 76(1):89-97. PubMed ID: 30553611
[TBL] [Abstract][Full Text] [Related]
13. [COST ANALYSIS OF ANDROGEN DEPRIVATION THERAPY AND DRUGS FOR CASTRATION-RESISTANT PROSTATE CANCER].
Nishizawa K; Hattahara K; Onishi H; Yoshida T
Nihon Hinyokika Gakkai Zasshi; 2021; 112(2):53-57. PubMed ID: 35444081
[TBL] [Abstract][Full Text] [Related]
14. A simple prognostic model involving prostate-specific antigen, alkaline phosphatase and albumin for predicting the time required to progress to castration-resistant prostate cancer in patients who received androgen deprivation therapy.
Lv W; Shang H; Pei X; Chen Y; Xie H; He D; Wang X; Li L
Int Urol Nephrol; 2017 Jan; 49(1):61-67. PubMed ID: 27837416
[TBL] [Abstract][Full Text] [Related]
15. Clinical predictors of survival in men with castration-resistant prostate cancer: evidence that Gleason score 6 cancer can evolve to lethal disease.
Nakabayashi M; Hayes J; Taplin ME; Lefebvre P; Lafeuille MH; Pomerantz M; Sweeney C; Duh MS; Kantoff PW
Cancer; 2013 Aug; 119(16):2990-8. PubMed ID: 23719969
[TBL] [Abstract][Full Text] [Related]
16.
Alzoubi A; Al Bashir S; Smairat A; Alrawashdeh A; Haddad H; Kheirallah K
J Med Life; 2023 Apr; 16(4):593-598. PubMed ID: 37305830
[TBL] [Abstract][Full Text] [Related]
17. Alkaline phosphatase velocity predicts overall survival and bone metastasis in patients with castration-resistant prostate cancer.
Hammerich KH; Donahue TF; Rosner IL; Cullen J; Kuo HC; Hurwitz L; Chen Y; Bernstein M; Coleman J; Danila DC; Metwalli AR
Urol Oncol; 2017 Jul; 35(7):460.e21-460.e28. PubMed ID: 28410987
[TBL] [Abstract][Full Text] [Related]
18. Serum follicle-stimulating hormone levels predict time to development of castration-resistant prostate cancer.
Hoare D; Skinner TA; Black A; Robert Siemens D
Can Urol Assoc J; 2015; 9(3-4):122-7. PubMed ID: 26085869
[TBL] [Abstract][Full Text] [Related]
19. Pre-existing Castration-resistant Prostate Cancer-like Cells in Primary Prostate Cancer Promote Resistance to Hormonal Therapy.
Cheng Q; Butler W; Zhou Y; Zhang H; Tang L; Perkinson K; Chen X; Jiang XS; McCall SJ; Inman BA; Huang J
Eur Urol; 2022 May; 81(5):446-455. PubMed ID: 35058087
[TBL] [Abstract][Full Text] [Related]
20. Predictors of castration-resistant prostate cancer after dose-escalated external beam radiotherapy.
Spratt DE; Zumsteg ZS; Pei X; Romesser PB; Yamada J; Kollmeier MA; Woo K; Zhang Z; Zelefsky MJ
Prostate; 2015 Feb; 75(2):175-82. PubMed ID: 25327412
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]